The market for cell-based assays is driven by the preference
over biochemical assays and animal models and the emergent 3D cell-based assay
techniques in cell-based assays.
There has been a substantial rise in the costs to develop a new drug in recent
years. This is specially observed when a new compound enters animal testing. The
use of animals in experimentation is becoming dearer, due to limitations such as
high costs involved in breeding and acquisition of animals, due to the
complexity of procedures involved in the in vivo testing, and several other
ethical issues and legal issues associated with it. Moreover the traditional
biochemical assays also posses many limitations. To counteract these issues
there has been a paradigm shift towards the use of cell-based assays.
The consumables formed the largest product segment of the total cell-based assays market in 2013, which includes assay kits and reagents, microplates and cell lines. The largest contribution of consumables was attributed to the large volume market of reagents and assay kits; where most of the innovation is taking place. Drug discovery was the most prominent application of cell-based assays. Within drug discovery, lead identification and optimization accounted for the largest share in 2013. With respect to end users, the pharmaceutical and biotechnology companies commanded the largest share in 2013. These industries are focusing on screening extensive libraries of compounds that could become leads for potential drug candidates. The screening process has helped the pharmaceutical companies to run more cost and time efficient methods.
For accurate results, the low cost label-free technology in cell based assays has emerged as a momentous technology that has been driving the growth of cell-based assay market. With the advancement in the cell stem cell culture, induced pluripotent stem cells will be emerging in near future. With the increasing demand of emergent 3D cell-based assay, it is estimated to be the fastest growing technology in the next five years.
North America accounted for the largest share of the global cell-based assay market in 2013. The presence of a large number of market players along with government funding for drug discovery and increasing number of public-private partnerships are the factors driving the North American cell-based assay market. Countries such as India and China serve as new revenue pockets for the cell-based assay market. Healthcare reforms, government initiatives, growing awareness and increasing investments in drug discovery are encouraging the rising acceptance and adoption of the cell-based assay technology in these regions. The emerging countries in Asia such as China and India will register high growth in the coming years; this can be attributed to the low development costs offered by these nations. Moreover, clinical research organizations are growing at fastest rate and more inclined to set their pace in these nations.
The consumables formed the largest product segment of the total cell-based assays market in 2013, which includes assay kits and reagents, microplates and cell lines. The largest contribution of consumables was attributed to the large volume market of reagents and assay kits; where most of the innovation is taking place. Drug discovery was the most prominent application of cell-based assays. Within drug discovery, lead identification and optimization accounted for the largest share in 2013. With respect to end users, the pharmaceutical and biotechnology companies commanded the largest share in 2013. These industries are focusing on screening extensive libraries of compounds that could become leads for potential drug candidates. The screening process has helped the pharmaceutical companies to run more cost and time efficient methods.
For accurate results, the low cost label-free technology in cell based assays has emerged as a momentous technology that has been driving the growth of cell-based assay market. With the advancement in the cell stem cell culture, induced pluripotent stem cells will be emerging in near future. With the increasing demand of emergent 3D cell-based assay, it is estimated to be the fastest growing technology in the next five years.
North America accounted for the largest share of the global cell-based assay market in 2013. The presence of a large number of market players along with government funding for drug discovery and increasing number of public-private partnerships are the factors driving the North American cell-based assay market. Countries such as India and China serve as new revenue pockets for the cell-based assay market. Healthcare reforms, government initiatives, growing awareness and increasing investments in drug discovery are encouraging the rising acceptance and adoption of the cell-based assay technology in these regions. The emerging countries in Asia such as China and India will register high growth in the coming years; this can be attributed to the low development costs offered by these nations. Moreover, clinical research organizations are growing at fastest rate and more inclined to set their pace in these nations.
No comments:
Post a Comment